An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer
Administered By
Awarded By
Contributors
- Hoimes, Christopher Principal Investigator
Start/End
- September 25, 2020 - October 19, 2025